{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:00Z","timestamp":1789014480970,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00415-022-11316-3","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T10:05:49Z","timestamp":1661335549000},"page":"6597-6604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Generalization of ocular myasthenia gravis 10\u00a0years after onset"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-5818","authenticated-orcid":false,"given":"Antoine","family":"Gu\u00e9guen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Hijazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Lamirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vignal-Clermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"11316_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141\u2013149","journal-title":"Muscle Nerve"},{"key":"11316_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A et al (1997) Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62:156\u2013162","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11316_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60:243\u2013248","journal-title":"Arch Neurol"},{"key":"11316_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","volume":"273","author":"Y-H Hong","year":"2008","unstructured":"Hong Y-H, Kwon S-B, Kim B-J et al (2008) Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci 273:10\u201314","journal-title":"J Neurol Sci"},{"key":"11316_CR5","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER (2015) Prognosis of ocular myasthenia gravis. Ophthalmology 122:1517\u20131521","journal-title":"Ophthalmology"},{"key":"11316_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025899","volume":"100","author":"J Witthayaweerasak","year":"2021","unstructured":"Witthayaweerasak J, Rattanalert N, Aui-Aree N (2021) Prognostic factors for conversion to generalization in ocular myasthenia gravis. Medicine (Baltimore) 100:e25899. https:\/\/doi.org\/10.1097\/MD.0000000000025899","journal-title":"Medicine (Baltimore)"},{"key":"11316_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever","year":"1983","unstructured":"Bever CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14:516\u2013519","journal-title":"Ann Neurol"},{"key":"11316_CR8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","volume":"52","author":"HJ Oosterhuis","year":"1989","unstructured":"Oosterhuis HJ (1989) The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 52:1121\u20131127","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11316_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","volume":"77","author":"A Evoli","year":"1988","unstructured":"Evoli A, Tonali P, Bartoccioni E, Lo Monaco M (1988) Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 77:31\u201335","journal-title":"Acta Neurol Scand"},{"key":"11316_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2017.09.036","volume":"382","author":"ME Farrugia","year":"2017","unstructured":"Farrugia ME, Cleary M, Carmichael C (2017) A retrospective study of acetylcholine receptor antibody positive ocular myasthenia in the west of Scotland. J Neurol Sci 382:84\u201386","journal-title":"J Neurol Sci"},{"key":"11316_CR11","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","volume":"265","author":"F Li","year":"2018","unstructured":"Li F, Hotter B, Swierzy M, Ismail M, Meisel A, R\u00fcckert J-C (2018) Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol 265:2773\u20132782","journal-title":"J Neurol"},{"key":"11316_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2018","unstructured":"Teo KY, Tow SL, Haaland B et al (2018) Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve 57:756\u2013760","journal-title":"Muscle Nerve"},{"key":"11316_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mus.25971","volume":"57","author":"SK Kamarajah","year":"2018","unstructured":"Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, Sivaguru A (2018) Ocular presentation of myasthenia gravis: a natural history cohort. Muscle Nerve 57:622\u2013627","journal-title":"Muscle Nerve"},{"key":"11316_CR14","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ (2009) Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 256:1314\u20131320","journal-title":"J Neurol"},{"key":"11316_CR15","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.4103\/0366-6999.166032","volume":"128","author":"LL Wang","year":"2015","unstructured":"Wang LL, Zhang Y, He ML (2015) Clinical features and prognosis of ocular myasthenia gravis patients with different phenotypes. Chin Med J (Engl) 128:2682\u20132684","journal-title":"Chin Med J (Engl)"},{"key":"11316_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","volume":"9","author":"X Huang","year":"2018","unstructured":"Huang X, Li Y, Feng H, Chen P, Liu W (2018) Clinical characteristics of juvenile myasthenia gravis in southern China. Front Neurol 9:77. https:\/\/doi.org\/10.3389\/fneur.2018.00077","journal-title":"Front Neurol"},{"key":"11316_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F et al (2018) Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 128:15\u201324","journal-title":"Int J Neurosci"},{"key":"11316_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475\u2013490","journal-title":"Lancet Neurol"},{"issue":"6","key":"11316_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jama.1953.02940230001001","volume":"153","author":"D Grob","year":"1953","unstructured":"Grob D (1953) Course and management of myasthenia gravis. JAMA 153(6):529\u2013532","journal-title":"JAMA"},{"key":"11316_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar M (2006) A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 16:459\u2013467","journal-title":"Neuromuscul Disord"},{"key":"11316_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/01658107.2019.1660686","volume":"44","author":"SH Wong","year":"2020","unstructured":"Wong SH, Eggenberger E, Cornblath W et al (2020) Preliminary findings of a dedicated ocular myasthenia gravis rating scale: the OMGRate. Neuro-Ophthalmology 44:148\u2013156","journal-title":"Neuro-Ophthalmology"},{"key":"11316_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425","journal-title":"Neurology"},{"key":"11316_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","volume":"21","author":"E Kerty","year":"2014","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE (2014) EFNS\/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol 21:687\u2013693","journal-title":"Eur J Neurol"},{"key":"11316_CR24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","volume":"53","author":"MJ Kupersmith","year":"1996","unstructured":"Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H (1996) Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 53:802\u2013804","journal-title":"Arch Neurol"},{"key":"11316_CR25","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","volume":"89","author":"MJ Kupersmith","year":"2005","unstructured":"Kupersmith MJ (2005) Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 89:1330\u20131334","journal-title":"Br J Ophthalmol"},{"key":"11316_CR26","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ (2009) Ocular myasthenia gravis: treatment successes and failures in patient with long-term follow-up. J Neurol 256:1311\u20131320","journal-title":"J Neurol"},{"key":"11316_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2012.06780.x","volume":"1275","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Wolfe GI, McDermott MP, Tawil R (2012) Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 1275:17\u201322","journal-title":"Ann N Y Acad Sci"},{"key":"11316_CR28","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/archneur.64.12.1794","volume":"64","author":"A Gregg","year":"2007","unstructured":"Gregg A (2007) Treating ocular myasthenia gravis with inadequate evidence. Arch Neurol 64:1794\u20131795","journal-title":"Arch Neurol"},{"key":"11316_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM (2004) The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 217:131\u2013133","journal-title":"J Neurol Sci"},{"key":"11316_CR30","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487\u20131489","journal-title":"Neurology"},{"key":"11316_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16\u201323","journal-title":"Neurology"},{"key":"11316_CR32","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 26:1054\u20131059","journal-title":"Neurology"},{"key":"11316_CR33","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","volume":"48","author":"A Vincent","year":"1985","unstructured":"Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48:1246\u20131252","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11316_CR34","first-page":"257","volume":"49","author":"A Vincent","year":"1982","unstructured":"Vincent A, Newsom-Davis J (1982) Acetylcholine receptor antibody characteristics in myasthenia gravis, I: patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 49:257\u2013265","journal-title":"Clin Exp Immunol"},{"key":"11316_CR35","first-page":"1170","volume":"72","author":"CE Peeler","year":"2015","unstructured":"Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT (2015) Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. Arch Neurol 72:1170\u20131174","journal-title":"Arch Neurol"},{"key":"11316_CR36","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","volume":"69","author":"S Jacob","year":"2012","unstructured":"Jacob S, Viegas S, Leite MI et al (2012) Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 69:994\u20131001","journal-title":"Arch Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11316-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11316-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11316-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T12:07:56Z","timestamp":1667131676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11316-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["11316"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11316-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antoine Gu\u00e9guen, Benoit Hijazi, Kevin Zuber, Romain Deschamps, Cedric Lamirel, Catherine Vignal-Clermont and Olivier Gout declare no conflicts of interest for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Local Ethics Committee (CE_20161027_22_AGN) approved this study that is registered at ClinicalTrials.gov (no. NCT04667650 (MYASTEN)).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}